Skip to main content
. 2021 Oct 22;6(20):e152468. doi: 10.1172/jci.insight.152468

Figure 6. PD-1 antibody ImmTAAI molecules bound to antigen-presenting cells inhibit primary human CD4+ T cells.

Figure 6

(A) PD-1 agonist ImmTAAI binding to Raji-A2 target cells was analyzed by flow cytometry (n = 2 and representative of 3 independent experiments). (B and C) PD-1 agonist ImmTAAI titrations were preincubated for 1 hour with PPI15–24 peptide–pulsed or nonpulsed SEB-loaded Raji-A2 cells. Preactivated T cells were added to the Raji-A2 cells and incubated for 48 hours. Supernatants were collected and IL-2 levels measured by ELISA. Dose response curves plotted to obtain IC50 values and relative inhibition of IL-2 release at 100 nM ImmTAAI was plotted for pulsed (+ PPI15–24) versus nonpulsed target cells (n = 3 and representative of 3 independent experiments). Data are plotted as mean ± SD and were compared by 2-way ANOVA with repeated measures and Tukey’s or Sidak’s multiple-comparison test. **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.